Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex Has Valid Data

In preclinical trials, the compound [blarcamesine] “has been shown to increase autophagy through ULK1 phosphorylation and to reduce proteotoxicity by decreasing protein aggregation in HeLa, HEK 293A cells, and C. elegans”.

Understand the importance of the findings in these “preclinical” trails, lab work that has been done with blarcamesine in a) HeLa cells, b) HEK 293a cells, and c) in the round worm Caenorhabditis elegans. Quite significant.

HeLa cells are an immortalized human cell line used in scientific research. These are not microbial or non-human cells; real human cells. Findings from research with these are more likely to be valid than studies testing drugs on microbes or non-human cell lines.

HEK 293 cells are an immortalized cell line derived from HEK cells isolated from a female fetus. As with HeLa cells, they are authentically human. Study results from them more likely to be valid in subsequent studies in living humans.

Then, studies of blarcamesine in the lab roundworm Caenorhabditis elegans. C. elegans is one of the most commonly used multicellular organisms in the study of aging processes.

As I have long contended, Anavex has copious amounts of in-house clinical study data on these and similar cell lines and organisms which have conclusively shown blarcamesine’s ability to slow or ameliorate aging and degenerative processes. This is because blarcamesine, with its unique activation of the sigma-1 receptor protein, allows that protein to then facilitate a diversity of consequent downstream cell-maintenance processes (including autophagy). Blarcamesine fixes a diversity of pathological processes in animal and human cells. Nothing magical about it. As the studies in these cell lines and the roundworm indicate, blarcamesine does, indeed, fix pathological things happening with proteins, with gene expression, and other anomalous pathogenic pathways.